S. Vitello

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

Alfredo Falcone, Sergio Ricci, I. Brunetti et al. · Journal of Clinical Oncology · 2007 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Chiara Cremolini, Fotios Loupakis, C. Antoniotti et al. · Annals of Oncology · 2015 · 194 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Chiara Cremolini, Fotios Loupakis, Gianluca Masi et al. · Annals of Oncology · 2016 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

Alfredo Falcone, Gianluca Masi, I. Brunetti et al. · Journal of Clinical Oncology · 2006 · 25 citations

Medicine, Oncology, Pharmacology +16